Background
Introduction
Chordoma is a primary bone cancer believed to arise from the remnants of the notochord, a developmental structure located along the midline that defines the primitive axis of the embryo [1] [2] [3] . Consistent with its origin, chordomas are largely restricted to opposing ends of the axial skeleton with the majority found at the sacrum and skull base. Histologically they are characterized by a vacuolated or "physaliphorous," morphology [4, 5] . Chordomas are slow-growing, low-grade bone cancers characterized by frequent local recurrence. Standard therapy consists of surgical resection, but due to the critical location of the tumor and its invasiveness, complete resection is frequently infeasible. Local control presents a major clinical challenge in the management of chordomas and recurrence eventually leads to the patient's demise. The median survival after diagnosis is 6-7 years, with 5-and 10-year survival rates of 68% and 40%, respectively [1, 3] . Adjuvant therapy consists of radiation therapy, primarily stereotactic delivery of gamma radiation or proton beam radiotherapy [3, 6, 7] . These delivery methods are preferred due to the high doses required to achieve tumor control, the radiosensitive nature of the adjacent structures, and favorable dose fall off compared to conventional radiotherapy. However, the poor overall prognosis makes the development of effective adjuvant treatment regimens critical to improving patient survival.
Although chordomas are considered to be relatively resistant to chemotherapy, there are case reports of occasional response [8] [9] [10] . The only prospectively evaluated pharmacotherapeutic approaches consist of three phase II clinical trials. A topoisomerase I inhibitor, 9-nitrocamptothecin, was investigated in 15 patients and appeared to delay progression of disease [11] . Following the immunohistochemical demonstration that PDGFR is activated in a majority of chordomas, patients with chordoma were treated with imatinib mesylate, a tyrosine kinase inhibitor active against PDGFR, BCR-ABL, and KIT [12, 13] . All participating subjects' tumor showed phosphorylation of the PDGFR. The investigators noted 1 partial response and 35 subjects with stable disease from a total of 50. More recently, lapatinib was investigated in subjects with advanced EGFR-positive chordoma. Six subjects representing 33% of total demonstrated partial response [14] . These experiences show the potential role of chemotherapy in improving outcome for patients with chordoma, although identification of more effective strategies is needed.
We have previously observed that PDGF is both mitogenic and motogenic for chordoma cells cultured from acutely resected surgical specimens [15] . Based on our observation of in vitro intertumoral variation in response to recombinant PDGF protein and PDGFR inhibition and the results of the imatinib clinical trial, we hypothesized that chordomas resistant to PDGFR inhibition may possess downstream activation of the pathway.
Materials and Methods

Patients and tumor tissues
The University of Pittsburgh Institutional Review Board approved the study, "Prospective and Retrospective Analysis of Chordoma Tissues and Records for Determination of Growth and Invasive Mechanisms." Written informed consents were obtained from all subjects prior to surgery. For minors, written consents were obtained from parents/guardians. The process was documented by the investigator and research coordinator. The IRB approved the consenting procedure. All tissues included in the study were clinically confirmed to be chordomas by a pathologist. Tumor specimens were collected prospectively after obtaining informed consent from 23 subjects with chordoma. Resected tumor tissue was immediately placed into sterile DMEM-F12 (GIBCO-Invitrogen, La Jolla, CA) tissue culture medium on ice and transported to the laboratory. Tumors were minced with a scalpel and mechanically dissociated by trituration.
Cell culture
Chordoma cells were cultured in DMEM/F12 medium supplemented with 2 mM glutamine, 1 mM sodium pyruvate, 100 U/ml penicillin, 100 μg/ml streptomycin (Gibco BRL, Gaithersburg, MD), and 10% heat inactivated fetal bovine serum (Gibco BRL) in a humidified incubator at 37 degrees C. Chordoma cells were identified by the characteristic physaliphorous morphology and expression of brachyury by immunohistochemistry and immunoblot. Cells were passaged upon achieving confluence and used up to 10 passages as long as they retained the physaliphorous morphology.
Chordoma cell lines UCH-1 and UCH-2 were obtained from the Chordoma Foundation. UCH-1 and UCH-2 cells were grown on plates coated with 0.005% collagen (Sigma) in a 4:1 mixture of Iscove's modified Dulbecco's medium (Invitrogen) and RPMI-1640 (Sigma) media containing 10% fetal bovine serum, 1 mM L-glutamine, and 26 mM sodium bicarbonate in a 37°C humidified tri-gas incubator. Human glioma lines U87MG and T98G were purchased from American Tissue Type Culture Collection (Manassas, VA, USA) and cultured as previously described [16] .
Hypoxic condition
Cells were incubated in a hypoxic chamber (Forma Scientific, Marietta, OH) with a 93:5:2 mixture of N 2 /CO 2 /O 2 . Deoxygenated media were prepared prior to each experiment by equilibrating with a hypoxic gas mixture containing 93% N 2 , 5% CO 2 , and 2% O 2 at 37 degrees C.
Antibodies and inhibitors
Anti-phospho-PI3K, anti-PI3K, anti-laminB antibody, anti-phospho-PDGF-α T720 , anti-PDGF-α, anti-phospho-PDGF-β T1009 , and anti-PDGF-β antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-HIF-1α antibody was purchased from BD Biosciences (San Jose, CA, USA Enzyme-linked immunosorbent assay (ELISA) for detection of vascular endothelial growth factor (VEGF)
Levels of VEGF protein in the media were determined by ELISA using a commercial kit (R&D Systems, Minneapolis, MN, USA) as previously described [16] .
Immunoblot and immunohistochemistry
These were performed as previously described [17] - [18] . Briefly, immunoblot analyses were performed by cell lysis in a buffer consisting of 20 mM Tris-HCl (pH 7.4, 150 mM NaCl, 1mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerol phosphate, 1m M Na 3 VO 4 , 1 μM/ml leupeptin and 1mM phenylmethylsulfonyl fluoride). After sonication, lysates were clarified by centrifugation at 12,000 x g for 10 minutes at 4°C, and protein content in the supernatant was measured according to the Bradford method. Aliquots (30-50 μg of protein per lane) of total protein were separated by 7.5-15% SDS-polyacrylamide gel electrophoresis and blotted onto nitrocellulose transfer membrane. Each membrane was blocked with 5% non-fat dry milk in TBS-T for 1 hour at room temperature, followed by incubation with the appropriate primary antibodies overnight at 4°C. After extensive washing with TBS-T, each membrane was incubated with horseradish peroxidase-conjugated secondary antibodies at 1:1000 dilution for 1 hour at room temperature in TBS-T. Detection was performed using chemiluminescence reagent. Immunohistochemistry on paraffin-embedded chordoma tumor specimen was performed using antibody against brachyury (R&D Systems). 5 μm sections were deparaffinized and underwent heat-induced epitope retrieval. Slides were then incubated with primary antibody and detected using avidin-biotin-peroxidase complex with 3,3'-diaminobenzidine as the chromogen.
Brachyury expression analyses
Brachyury was detected using both immunoblot and immunohistochemistry. Nuclear expression was confirmed by immunohistochemistry and by immunoblot performed on isolated nuclear protein fraction.
Nuclear extraction
We isolated nuclear proteins using a commercially available kit (Pierce Protein Biology Products, Rockford, IL) following the manufacturer's instructions.
PCR-based microsatellite LOH analysis
Manual microdissection of the tissue sample was performed and specimens with a minimum of 50% of tumor cells in a microdissection target were accepted for analysis. DNA was isolated using standard laboratory procedures. Optical density readings were obtained. The assay utilized 2 microsatellite markers on chromosome 10q23 near the PTEN locus (D10S520, D10S1173). PCR was performed and the PCR products were analyzed using capillary gel electrophoresis on GeneScan ABI 3730 (Foster City, CA). Relative fluorescence was determined for individual alleles and the ratio of peaks was calculated. Neoplastic tissue was then analyzed to detect loss of heterozygosity. As normal tissue was usually not available, peak height ratios falling outside of 2 standard deviations beyond the mean for each polymorphic allele paring were assessed as showing loss of heterozygosity.
Invasion assay
The BD BioCoat Matrigel Invasion Chamber assay system was used to study the effects of inhibitors on chordoma cell invasion (BD Biosciences, MA). Briefly, precoated filters (8 μm pore-size, Matrigel 100 μg/cm 2 ) were rehydrated and seeded with 2.5 x 10 4 cells in 500 μl of medium with or without inhibitors in triplicates into the upper part of each chamber. The lower compartment was filled with 750 μl of serum-free DMEM/F-12 supplemented with 0.1% BSA. After incubation for 18 h at 37 degrees C, non-invaded cells on the upper surface of the filter were wiped with a cotton swab, and migrated cells on the lower surface of the filter were fixed and stained with Diff-Quick kit. Invasiveness was determined by counting cells in five microscopic fields per well, and the extent of invasion was expressed as an average number of cells per microscopic field.
Cell proliferation assay 
Annexin V-PE and 7-AAD flow cytometry
The effects of PTEN expression on PDGFR inhibitor-mediated effects on apoptosis were assessed by Annexin V-PE and 7-AAD flow cytometry. UCH-1 and C18 cells were infected with Ad-PTEN or Ad-con for 24 h and then were treated with PDGFR inhibitor for 48 h. Cells were harvested and stained with Annexin V-PE and 7AAD according to the manufacturer's instructions. Cell samples were analyzed on a FACsan flow cytometer and apoptotic fractions were determined.
Vectors and Transfections
Adenoviruses encoding wild-type PTEN (Ad-PTEN) and control adenovirus (Ad-control) were constructed as described previously [19, 20] . Cells were infected with adenovirus vectors (MOI = 10) for 24 h before treatment with PDGFR inhibitor.
Statistical analysis
Statistical analysis was carried out using Graphpad InStat 3 software (GraphPad Software, Inc., San Diego, CA, USA). Results were considered statistically significant at p < 0.05.
Results
Patient characteristics
Chordoma tissues from 23 patients were analyzed (Table 1 ). There were 18 men and 5 women. Ages ranged from 6 to 77 years. Seventeen were cases at first presentation and 6 were recurrent tumors. All specimens showed nuclear expression of brachyury by immunohistochemistry. We show one representative immunohistochemical staining and four immunoblots with control cancer cell lines that do not express brachyury (S1 (Fig 1) . Chordoma tissues without LOH at 10q23 demonstrated PTEN protein expression (Fig 1) . Previously characterized cell lines served as positive and negative controls (Fig 1) . (Fig 1) . To determine the effect of PTEN status on chordoma cellular response to PDGFR inhibition, chordoma cells from PTEN deficient and wild type tumors were exposed to a PDGF receptor tyrosine kinase inhibitor. We investigated the effect of PDGFR inhibition on proliferative rate and invasive capacity. We did not detect a significant difference in proliferative rate in response to the PDGFR inhibitor (Fig 1) . Also, the in vitro invasive capacity of PTEN wild type and PTEN deficient tumors were similar (Fig 1) . However, PTEN deficient tumors showed greater resistance to PDGFR inhibition on invasion compared to PTEN wild type cells (Fig 1) . 
Chordoma cells deficient for PTEN show increased in vitro growth and resistance to PDGFR inhibition
PTEN restoration results in attenuation of growth
To confirm that PTEN deficiency drives chordoma proliferation and resistance to PDGFR inhibition and is not merely a bystander, we restored PTEN expression in two chordoma cell lines lacking PTEN. Lines C18, C21 (primary culture) and UCH-1 (established chordoma cell line) showed attenuation of proliferative rate (Fig 2 and S5 Fig) . Increase in apoptosis and attenuation of invasive capacity was only seen in the primary culture C18 and not with UCH-1, an established cell line (Fig 3) . However, PTEN restoration established sensitivity to PDGR inhibition in both cell lines (Fig 3 and S2 Fig) .
HDAC inhibition attenuates expression of the hypoxia inducible factor 1 alpha (HIF-1α) and results in decreased chordoma cell proliferation and invasion
Chordomas harbor regions of intratumoral hypoxia that can contribute to treatment resistance. [21, 22] To identify potential therapeutics effective in low oxygen setting, we characterized in vitro propagation of chordoma cells at 2% oxygen and observed increased proliferative rate (Fig 4) and level of vascular endothelial growth factor (VEGF), a transcriptional target of HIF-1α (Fig 4) . Treatment with HDAC inhibitor LBH589 (25 nM) led to reduction of HIF-1α level (Fig 4) .
Combined PDGFR and HDAC inhibition is associated with reduction in invasion and proliferation
Chordoma cells with intact PTEN expression and those deficient for PTEN both demonstrate greater potential therapeutic response to the combination of PDGFR inhibitor and HDAC inhibition (Fig 5) . The benefit of combined inhibition was particularly significant for attenuation of invasion (Fig 5) .
Discussion
Identifying the determinants of tumor resistance to therapy is important for improving patient care and will likely lead to better understanding of the underlying biology [23] . In this study, we profiled 23 chordoma specimens, and investigated mechanisms of in vitro proliferation and invasion of chordoma cells to identify effective combinatorial regimens. Because availability of established chordoma cell lines is limited, we relied on primary culture specimens. We found that primary culture of chordoma can be established, and PTEN is lost in a subset of chordoma [24] . This loss leads to enhanced in vitro growth and relative resistance to PDGFR inhibition compared to chordomas with intact PTEN expression. Interestingly, we observed that PTEN loss was associated with greater resistance to proliferation compared to invasion. Such observation may in part explain paucity of tumor shrinkage, but high number of subjects with stable disease with the use of single agent imatinib for chordoma [13] . Determining the functional significance of PTEN loss in chordoma and the observation that such loss may result in resistance to upstream inhibition may provide design of therapeutic strategies to overcome such disruptions. This study was performed because: 1) experience from a clinical trial demonstrated variable clinical response of chordomas to PDGFR inhibition despite all tumors showing activation of PDGFR; and 2) our in vitro laboratory observation of intertumoral variation in growth rate and response to PDGR inhibition of chordoma cells. To identify the potential molecular basis for such observations, we profiled chordoma specimens and investigated the in vitro growth characteristics. All histologically confirmed chordoma specimens demonstrated nuclear expression of brachyury. Because brachyury expression becomes restricted to the notochord during development, this marker is useful in distinguishing chordomas from other tumors [25] [26] [27] .
Addition of recombinant PDGF to the chordoma cells led to downstream activation of appropriate signaling pathways (S3 Fig). We observed LOH at 10q23, a locus that contains the PTEN gene, in a subset of chordomas. LOH at 10q23 was statistically significant for increased Ki-67, an established negative prognostic indicator for chordoma ( S4 Fig). PTEN gene encodes a phosphatidylinositol-3,4,5-triphosphate (PIP3) phosphatase that functions as an important negative regulator of the PI3K-Akt signaling pathway. Considering that the PI3K-Akt network activity is amplified in many human cancers, it is not a surprise that PTEN is one of the most commonly disrupted tumor suppressors in cancers [28] . Investigations into the pattern of PTEN loss in cancers show that LOH is a significantly more common finding than biallelic gene inactivation [29] . Subsequent studies showed that the loss of heterozygosity at the PTEN locus is important in tumorigenesis because PTEN is a haploinsufficient tumor suppressor [29] [30] [31] . In half of the chordoma cases with LOH at 10q23, we observed absence of PTEN protein expression. There are several possible explanations for loss of PTEN protein with deletion of one allele. Mutation of the PTEN promoter on the retained allele can result in gene silencing [32] . Also epigenetic mechanisms, specifically methylation of the promoter have been described [33] [34] [35] [36] .
It has been previously demonstrated that PTEN deficient cells exhibit increased proliferation, reduced apoptosis, and enhanced migration [37] [38] [39] . Chordoma cells lacking PTEN protein expression indeed showed increased in vitro growth rate and shorter doubling time compared with PTEN wild type chordoma cells. PTEN loss was associated with greater resistance to PDGFR inhibition on invasion-migration assay in comparison to PTEN wild type chordoma. Such observations are intriguing because chordomas are not rapidly growing tumors and clinical progression frequently involves slow but insidious invasion into surrounding structures. Another potentially important clinical consideration resulting from PTEN deficiency concerns genetic instability. Loss of PTEN has been linked to genetic instability of cancers through a mechanism of CHK1 phosphorylation from unopposed activation of AKT [40] . This leads to accumulation of DNA double-strand breaks due to cytoplasmic Cell proliferation assay assessed by MTS method using C18 (PTEN +/-) cells demonstrating significantly decreased proliferation in response to HDAC inhibition and combined treatment with a PDGFR inhibitor compared to controls. This is representative of 3 independent of experiments. *P<0.05, Two sample independent student's t test. (B) Cell proliferation assays assessed by MTS method using UCH1 (PTEN +/-) and UCH2 (PTEN +/-) cells demonstrating significantly decreased proliferation in response to HDAC inhibition and combined treatment with a PDGFR inhibitor compared to controls. This is representative of 3 independent of experiments. *P<0.05, Two sample independent student's t test. (C) Representative matrigel invasion assays with the C18 cell line (PTEN +/-) and UCH1 cell line (PTEN +/-), respectively, demonstrating significant decrease in invasion in response to PDGFR inhibition, HDAC inhibition and PDGFR and HDAC inhibition together. These images are representative of 3 independent experiments. *P<0.05, Two sample independent student's t test compared to untreated control. **P<0.05, Two sample independent student's t test compared to PDGFR inhibitor alone.
doi:10.1371/journal.pone.0134426.g005
Development of Combinatorial Therapy for Chordoma sequestration of CHK1 [41] . In agreement with experimental findings, increased aneuploidy is observed in human cancers with low PTEN expression [40, 42, 43] . It will be interesting to see if chordomas with PTEN loss demonstrate greater genetic instability. Also, as expected from inhibition of CHK1, PTEN deficient cells show impaired DNA repair checkpoint regulations in response to ionizing radiation [40] . Because chordoma patients are often treated with external beam radiation therapy after surgery, there is a theoretical risk for tumors that have PTEN loss to accelerate genetic instability upon exposure to radiation.
To further investigate the functional significance of PTEN loss in chordomas, we restored its expression in PTEN disrupted tumors using an adenoviral vector. Reintroduction of PTEN was associated with reduction in proliferation and enhanced therapeutic sensitivity to PDGFR inhibitor. However, in vivo reconstitution of PTEN is technically inefficient at this time. Due to this technical limitation, we sought to identify another target that could act in concert with PDGFR inhibition. Considering the consequences of PTEN loss, inhibitors of Akt and mTOR were investigated serially in combination with PDGFR inhibitor. Neither combination was compelling. mTOR inhibition merely resulted in reduction in the size of the chordoma cells and had little effect on proliferation and invasion (Data not shown).
We chose to move forward with the combination of PDGFR and HDAC inhibition because: 1) HDAC inhibition has shown to attenuate cell migration, and chordomas for the most part progress by local invasion; 2) Chordomas are characterized by regions of intratumoral hypoxia and HDAC inhibition can down regulate expression of HIF-1α, a master regulator of the hypoxic response [21] ; 3) Receptor tyrosine kinase signaling pathway overlaps with hypoxic signaling cascade and PTEN loss is associated with enhance HIF-1α expression [44] ; 4) HDAC inhibitor mediated cytotoxic mechanism is distinct from tyrosine kinase inhibition. We observed that chordoma cells propagated at low oxygen tension had a proliferative advantage and expressed both HIF-1α and its downstream target, VEGF. HDAC inhibition led to reduction in chordoma cell proliferation and invasion, and HIF-1α expression. A recent report describing cytotoxic activity of HDAC inhibitors in chordoma further support our findings [45] . The combination of PDGFR and HDAC inhibitors demonstrated striking reduction in chordoma cell invasion, irrespective of PTEN status.
Our report illustrates the presence of therapeutically relevant genetic heterogeneity in chordoma. Intertumoral histologic heterogeneity is well recognized with descriptions of classic, chondroid, and undifferentiated types. However, because most patients had skull base tumors, it will be important to confirm our findings in sacral chordomas. This is particularly important because the regional developmental pattern of notochord shows contributions from distinctive cell types [46] . Nevertheless, within the chordomas of clival origin we found molecular heterogeneity that may have clinical relevance and allow for stratification of patients for therapy. The observation that PTEN loss grants a greater resistance to PDGFR inhibition on migration-invasion rather than growth was surprising but is consistent with the biological characteristics of the disease. Characterization of tumors to identify key loss and gain of functions will not only allow for selection of rational agents, but equally important is to define a more relevant endpoint to determine outcome. Future clinical studies of imatinib in chordoma may benefit from a PTEN subgroup analysis to determine rate of progression with less emphasis on response. Finally, our findings provide compelling preclinical rationale for a biomarker-driven clinical study of combined inhibition of PDGFR and HDAC in chordomas.
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